Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

Publication | Open Access

DOI Full Paper Access

194

Citations

References

2019

Year

Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, Peter Rossing, C. David Sjöström, David C. Wheeler, Anna Maria Langkilde, Hiddo J.L. Heerspink

The Lancet Diabetes & Endocrinology

Metabolic SyndromeDiabetes ManagementRenal FunctionRenal DiseaseAlbuminuria-lowering EffectMedicineDiabetesPharmacologyType 2Diabetic Kidney DiseaseDiabetes MellitusChronic Kidney Disease